

CORRECTION

Correction: Improved residual fat malabsorption and growth in children with cystic fibrosis treated with a novel oral structured lipid supplement: A randomized controlled trial

Virginia A. Stallings, Alyssa M. Tindall, Maria R. Mascarenhas, Asim Maqbool, Joan I. Schall

The Competing Interests statement is incorrect. The correct Competing Interests statement is as follows: LXS (now known as Encala™) was a product of BioMolecular Products, Inc and was used for the clinical trial. Envara Health was founded in 2018 to develop therapeutic nutrition products related to the licensed LXS (now Encala™) technology. After study completion, VAS co-founded Envara Health and serves as a consultant.

Reference

1. Stallings VA, Tindall AM, Mascarenhas MR, Maqbool A, Schall JI (2020) Improved residual fat malabsorption and growth in children with cystic fibrosis treated with a novel oral structured lipid supplement: A randomized controlled trial. PLoS ONE 15(5): e0232685. <https://doi.org/10.1371/journal.pone.0232685> PMID: 32384122



OPEN ACCESS

Citation: Stallings VA, Tindall AM, Mascarenhas MR, Maqbool A, Schall JI (2020)

Correction: Improved residual fat malabsorption and growth in children with cystic fibrosis treated with a novel oral structured lipid supplement: A randomized controlled trial. PLoS ONE 15(9): e0239642. <https://doi.org/10.1371/journal.pone.0239642>

Published: September 17, 2020

Copyright: © 2020 Stallings et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.